Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 25-Sep-24 5:56 PM View:  | Cohen Joshua B Co-Chief Executive Officer Director | Amylyx Pharmaceuticals, Inc. (AMLX) | 23-Sep-24 | Option Exercise | 1,857 | $1.57 | $2,915.49 | < 1% 3.24M to 3.24M | |
| 16-Sep-24 5:30 PM View: | Frates James M Chief Financial Officer | Amylyx Pharmaceuticals, Inc. (AMLX) | 12-Sep-24 | Private Purchase | 40,000 | $2.53 | $101,368.00 | 18% 220.0K to 260.0K | |
| 16-Sep-24 5:39 PM View: | Cohen Joshua B Co-Chief Executive Officer Director | Amylyx Pharmaceuticals, Inc. (AMLX) | 12-Sep-24 | Option Exercise | 34,449 | $1.57 | $54,084.90 | 1% 3.2M to 3.24M | |
| 09-Sep-24 4:05 PM View: | Firestone Karen Director | Amylyx Pharmaceuticals, Inc. (AMLX) | 05-Sep-24 | Private Purchase | 50,000 | $2.13 | $106,590.00 | 1000% 5.0K to 55.0K | |
| 05-Sep-24 7:26 PM View: | Milne George M Jr Director | Amylyx Pharmaceuticals, Inc. (AMLX) | 03-Sep-24 | Private Purchase | 100,000 | $2.20 | $219,800.00 | 13% 758.57K to 858.57K | |
| 16-May-24 7:36 PM View: | Mazzariello Gina Chief Legal Officer | Amylyx Pharmaceuticals, Inc. (AMLX) | 15-May-24 | Sale (Planned) | 10,455 | $1.88 | $19,654.40 | (6%) 161.93K to 151.48K | |
| 16-May-24 7:37 PM View: | Quimi Daphne Director | Amylyx Pharmaceuticals, Inc. (AMLX) | 15-May-24 | Purchase | 2,250 | $1.89 | $4,252.27 | 82% 2.75K to 5.0K | |
| 16-May-24 7:37 PM View: | Quimi Daphne Director | Amylyx Pharmaceuticals, Inc. (AMLX) | 14-May-24 | Private Purchase | 2,750 | $1.88 | $5,183.75 | 100% 0 to 2.75K | |
| 18-Apr-24 8:20 PM View: | Klee Justin B. Co-Chief Executive Officer Director | Amylyx Pharmaceuticals, Inc. (AMLX) | 16-Apr-24 | Grant | 179,850 | -- | -- | 6% 2.96M to 3.14M | |
| 18-Apr-24 8:20 PM View: | Mazzariello Gina Chief Legal Officer | Amylyx Pharmaceuticals, Inc. (AMLX) | 16-Apr-24 | Grant | 80,560 | -- | -- | 99% 81.37K to 161.93K | |
| 18-Apr-24 8:19 PM View: | Bedrosian Camille L Chief Medical Officer | Amylyx Pharmaceuticals, Inc. (AMLX) | 16-Apr-24 | Grant | 96,910 | -- | -- | 166% 58.33K to 155.24K | |
| 18-Apr-24 8:23 PM View: | Frates James M Chief Financial Officer | Amylyx Pharmaceuticals, Inc. (AMLX) | 16-Apr-24 | Grant | 91,180 | -- | -- | 57% 161.31K to 252.5K | |
| 18-Apr-24 8:21 PM View: | Cohen Joshua B Co-Chief Executive Officer Director | Amylyx Pharmaceuticals, Inc. (AMLX) | 16-Apr-24 | Grant | 179,850 | -- | -- | 6% 3.02M to 3.2M | |
| 07-Mar-24 4:05 PM View: | Mazzariello Gina Chief Legal Officer | Amylyx Pharmaceuticals, Inc. (AMLX) | 05-Mar-24 | Market Sale | 1,540 | $18.73 | $28,841.00 | (2%) 82.91K to 81.37K | 11% |
| 07-Mar-24 4:05 PM View: | Frates James M Chief Financial Officer | Amylyx Pharmaceuticals, Inc. (AMLX) | 05-Mar-24 | Market Sale | 1,792 | $18.73 | $33,560.40 | (1%) 163.11K to 161.31K | 11% |
| 07-Mar-24 4:05 PM View: | Cohen Joshua B Co-Chief Executive Officer Director | Amylyx Pharmaceuticals, Inc. (AMLX) | 05-Mar-24 | Market Sale | 4,135 | $18.73 | $77,439.90 | (< 1%) 3.03M to 3.02M | 11% |
| 07-Mar-24 4:05 PM View: | Klee Justin B. Co-Chief Executive Officer Director | Amylyx Pharmaceuticals, Inc. (AMLX) | 05-Mar-24 | Market Sale | 4,135 | $18.73 | $77,439.90 | (< 1%) 2.96M to 2.96M | 11% |
| 28-Feb-24 6:44 PM View: | Frates James M Chief Financial Officer | Amylyx Pharmaceuticals, Inc. (AMLX) | 26-Feb-24 | Grant | 40,000 | -- | -- | 32% 123.11K to 163.11K | |
| 28-Feb-24 6:22 PM View: | Cohen Joshua B Co-Chief Executive Officer Director | Amylyx Pharmaceuticals, Inc. (AMLX) | 26-Feb-24 | Grant | 126,667 | -- | -- | 4% 2.9M to 3.03M | |
| 28-Feb-24 6:20 PM View: | Klee Justin B. Co-Chief Executive Officer Director | Amylyx Pharmaceuticals, Inc. (AMLX) | 26-Feb-24 | Grant | 126,667 | -- | -- | 4% 2.84M to 2.96M | |
| 28-Feb-24 6:13 PM View: | Mazzariello Gina Chief Legal Officer | Amylyx Pharmaceuticals, Inc. (AMLX) | 26-Feb-24 | Grant | 36,667 | -- | -- | 79% 46.24K to 82.91K | |
| 27-Feb-24 5:59 PM View: | Mazzariello Gina Chief Legal Officer | Amylyx Pharmaceuticals, Inc. (AMLX) | 23-Feb-24 | Market Sale | 2,838 | $18.76 | $53,230.70 | (6%) 49.08K to 46.24K | 11% |
| 29-Jan-24 4:38 PM View: | Milne George M Jr Director | Amylyx Pharmaceuticals, Inc. (AMLX) | 25-Jan-24 | Gift | 9,100 | -- | -- | (1%) 767.67K to 758.57K | |
| 18-Jan-24 4:50 PM View: | Milne George M Jr Director | Amylyx Pharmaceuticals, Inc. (AMLX) | 16-Jan-24 | Gift | 94,350 | -- | -- | (11%) 862.02K to 767.67K | |
| 11-Jan-24 5:10 PM View: | Cohen Joshua B Co-Chief Executive Officer Director | Amylyx Pharmaceuticals, Inc. (AMLX) | 09-Jan-24 | Market Sale | 5,841 | $16.33 | $95,372.40 | (< 1%) 2.91M to 2.9M | (2%) |
| 11-Jan-24 5:11 PM View: | Klee Justin B. Co-Chief Executive Officer Director | Amylyx Pharmaceuticals, Inc. (AMLX) | 09-Jan-24 | Market Sale | 5,841 | $16.33 | $95,372.40 | (< 1%) 2.84M to 2.84M | (2%) |
| 11-Jan-24 5:04 PM View: | Yeramian Patrick D Chief Medical Officer | Amylyx Pharmaceuticals, Inc. (AMLX) | 09-Jan-24 | Market Sale | 2,812 | $16.33 | $45,914.60 | (1%) 208.42K to 205.6K | (2%) |
| 11-Jan-24 5:11 PM View: | Frates James M Chief Financial Officer | Amylyx Pharmaceuticals, Inc. (AMLX) | 09-Jan-24 | Market Sale | 2,716 | $16.33 | $44,347.10 | (2%) 125.82K to 123.11K | (2%) |
| 29-Dec-23 4:07 PM View: | Olinger Margaret Chief Commercial Officer | Amylyx Pharmaceuticals, Inc. (AMLX) | 27-Dec-23 | Option Exercise | 25,000 | $0.37 | $9,250.00 | 10% 251.11K to 276.11K | |
| 19-Dec-23 4:37 PM View: | Firestone Karen Director | Amylyx Pharmaceuticals, Inc. (AMLX) | 15-Dec-23 | Private Purchase | 4,000 | $14.97 | $59,880.00 | 400% 1.0K to 5.0K | |
| 29-Nov-23 4:49 PM View: | Bedrosian Camille L Chief Medical Officer | Amylyx Pharmaceuticals, Inc. (AMLX) | 27-Nov-23 | Grant | 58,333 | -- | -- | 100% 0 to 58.33K | |
| 20-Nov-23 10:00 PM View: | Cohen Joshua B Co-Chief Executive Officer Director | Amylyx Pharmaceuticals, Inc. (AMLX) | 16-Nov-23 | Option Exercise | 63,694 | $1.57 | $99,999.60 | 2% 2.84M to 2.91M | |
| 02-Nov-23 3:33 PM View: | Frates James M Chief Financial Officer | Amylyx Pharmaceuticals, Inc. (AMLX) | 31-Oct-23 | Gift | 11,072 | -- | -- | 10% 114.75K to 125.82K | |
| 24-Aug-23 4:15 PM View: | Frates James M Chief Financial Officer | Amylyx Pharmaceuticals, Inc. (AMLX) | 23-Aug-23 | Option Exercise | 18,165 | $6.88 | $124,975.00 | 17% 107.66K to 125.82K | |
| 17-Aug-23 5:34 PM View: | Morningside Venture Investm... 10% Owner | Amylyx Pharmaceuticals, Inc. (AMLX) | 15-Aug-23 | Gift | 2,000,000 | -- | -- | (29%) 7.0M to 5.0M | |
| 17-Aug-23 4:35 PM View: | Mazzariello Gina Chief Legal Officer | Amylyx Pharmaceuticals, Inc. (AMLX) | 15-Aug-23 | Private Sale (Planned) | 6,164 | $20.88 | $128,686.00 | (11%) 55.25K to 49.08K | |
| 14-Jul-23 4:20 PM View: | Olinger Margaret Chief Commercial Officer | Amylyx Pharmaceuticals, Inc. (AMLX) | 12-Jul-23 | Option Exercise | 20,000 | $0.37 | $7,400.00 | 9% 231.11K to 251.11K | |
| 24-May-23 4:38 PM View: | Olinger Margaret Chief Commercial Officer | Amylyx Pharmaceuticals, Inc. (AMLX) | 22-May-23 | Gift | 1,580 | -- | -- | (< 1%) 232.69K to 231.11K | |
| 19-May-23 4:07 PM View: | Mazzariello Gina Chief Legal Officer | Amylyx Pharmaceuticals, Inc. (AMLX) | 17-May-23 | Gift | 500 | -- | -- | (< 1%) 55.75K to 55.25K | |
| 18-May-23 8:54 PM View: | Frates James M Chief Financial Officer | Amylyx Pharmaceuticals, Inc. (AMLX) | 16-May-23 | Option Exercise | 32,500 | $6.88 | $223,600.00 | 43% 75.16K to 107.66K | |
| 18-May-23 8:54 PM View: | Frates James M Chief Financial Officer | Amylyx Pharmaceuticals, Inc. (AMLX) | 16-May-23 | Planned Option Sale | 32,500 | $26.94 | $875,451.00 | (30%) 107.66K to 75.16K | |
| 17-May-23 4:58 PM View: | Yeramian Patrick D Chief Medical Officer | Amylyx Pharmaceuticals, Inc. (AMLX) | 15-May-23 | Planned Option Sale | 11,965 | $29.03 | $347,358.00 | (5%) 220.38K to 208.42K | |
| 17-May-23 4:58 PM View: | Yeramian Patrick D Chief Medical Officer | Amylyx Pharmaceuticals, Inc. (AMLX) | 15-May-23 | Option Exercise | 11,965 | $5.68 | $67,990.70 | 6% 208.42K to 220.38K | |
| 19-Apr-23 7:45 PM View: | Yeramian Patrick D Chief Medical Officer | Amylyx Pharmaceuticals, Inc. (AMLX) | 17-Apr-23 | Option Exercise | 49,579 | $0.99 | $49,058.40 | 24% 208.42K to 258.0K | |
| 19-Apr-23 7:45 PM View: | Yeramian Patrick D Chief Medical Officer | Amylyx Pharmaceuticals, Inc. (AMLX) | 17-Apr-23 | Planned Option Sale | 49,579 | $30.54 | $1,513,940.00 | (19%) 258.0K to 208.42K | |
| 31-Mar-23 4:05 PM View: | Morningside Venture Investm... 10% Owner | Amylyx Pharmaceuticals, Inc. (AMLX) | 29-Mar-23 | Private Sale | 29,048 | $30.45 | $884,512.00 | (< 1%) 7.03M to 7.0M | |
| 29-Mar-23 4:05 PM View: | Morningside Venture Investm... 10% Owner | Amylyx Pharmaceuticals, Inc. (AMLX) | 28-Mar-23 | Sale | 100,000 | $30.37 | $3,037,000.00 | (1%) 7.13M to 7.03M | |
| 29-Mar-23 4:05 PM View: | Morningside Venture Investm... 10% Owner | Amylyx Pharmaceuticals, Inc. (AMLX) | 27-Mar-23 | Private Sale | 60,964 | $30.50 | $1,859,560.00 | (< 1%) 7.19M to 7.13M | |
| 23-Mar-23 4:05 PM View: | Morningside Venture Investm... 10% Owner | Amylyx Pharmaceuticals, Inc. (AMLX) | 21-Mar-23 | Private Sale | 63,448 | $31.91 | $2,024,490.00 | (< 1%) 7.25M to 7.19M | |
| 20-Mar-23 8:22 PM View: | Firestone Karen Director | Amylyx Pharmaceuticals, Inc. (AMLX) | 16-Mar-23 | Purchase | 1,000 | $31.99 | $31,990.00 | 100% 0 to 1.0K |
